RAPID MICRO BIOSYSTEMS, INC. (RPID): Entry into a Material Definitive Agreement
RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rapid Micro Biosystems Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany LEXINGTON, Mass., November 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company prov
- Role
- target
- Counterparty
- Merck KGaA, Darmstadt, Germany
- Price per share
- $0.75 per share
- Consideration
- cash
- Expected close
- December 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
For RPID, the key tradable variables are the all-cash offer price, tender offer commencement and progress, satisfaction of the minimum tender condition, and the likelihood/timing of regulatory approvals and other customary closing conditions.
Market read
This is a primary takeover disclosure with a stated per-share cash price and a December 2026 closing expectation, which typically drives immediate repricing and deal-arb positioning in the target.
What to watch
Watch for tender offer mechanics, the minimum tender condition, and any shareholder litigation or regulatory conditions that could delay or alter closing terms.
Background
The article is an SEC Form 8-K describing Rapid Micro Biosystems’ entry into a material definitive agreement for Merck KGaA to acquire all outstanding shares.
Ticker impact
Rapid Micro Biosystems signed a definitive agreement to be acquired by Merck KGaA in an all-cash deal at $0.75 per share, expected to close in December 2026.
Likely upward pressure toward the offer price as the market prices deal certainty, with volatility around tender conditions and regulatory or litigation risks.
The filing discloses a definitive acquisition agreement, a specific all-cash price per share, and key closing conditions (tender offer, minimum tender condition, customary approvals).
Market effects
Highlights continued consolidation in life-sciences automation and microbial quality control tooling, potentially drawing attention to adjacent lab automation vendors.
Limited direct regional impact beyond US-listed takeover dynamics for the target.
Merck KGaA is the acquirer, reinforcing cross-border pharma supply-chain and compliance automation investment themes.
Counterpoint
The offer price may not fully hold if regulatory approvals or tender participation fall short, so the spread can widen even after a definitive agreement.
Key entities
- companyRapid Micro Biosystems, Inc.
US-listed target company signing a definitive all-cash acquisition agreement.
- companyMerck KGaA
German acquirer agreeing to purchase all outstanding shares of Rapid Micro Biosystems.
- companyEMD Holdings NewCo II, Inc.
Purchaser entity referenced for the tender offer process.

